Creative Biolabs Launches One-Stop ASO Development Services

In the rapidly evolving field of RNA therapeutics, researchers developing antisense oligonucleotides (ASOs) often grapple with technical hurdles such as achieving high binding affinity, overcoming enzymatic degradation, and ensuring tissue-specific delivery. These challenges can significantly slow translational progress. To address these bottlenecks, Creative Biolabs has announced the launch of its integrated, one-stop antisense oligonucleotide (ASO) development services. This comprehensive platform combines advanced bioinformatics, chemical synthesis, and rigorous preclinical validation to support global biotechnology companies and academic institutions.

Traditional ASO development is often fragmented, forcing researchers to coordinate with multiple vendors for design, synthesis, and animal testing, leading to extended timelines and data inconsistency. Creative Biolabs solves this by unifying the entire pipeline under one roof. The platform includes proprietary bioinformatic optimization using thermodynamic simulation and RNA secondary structure accessibility prediction to identify optimal target regions, mitigating off-target risks. It also offers advanced chemical modifications and synthesis, including versatile oligonucleotide architectures like Gapmers and steric-blocking oligos, with capabilities from milligram to multi-gram scales. Precision delivery is addressed through custom targeted delivery technologies such as GalNAc conjugation for liver targeting, Antibody-Oligonucleotide Conjugates (AOCs) for extrahepatic tissues, and specialized LNP formulations. Robust preclinical validation provides data-rich in vitro screening and in vivo PK/PD profiling.

“Many therapeutic pipelines stall because a high-affinity sequence fails under physiological conditions due to poor delivery or low stability,” stated the Chief Scientific Officer at Creative Biolabs. “Our one-stop platform eliminates these silos. By matching customized chemical modifications with precise conjugation chemistries early in the design phase, we significantly lower required doses and improve the safety profiles of our clients’ candidates.” With a robust portfolio of ready-to-use ASO products spanning oncology, genetic disorders, and neuromuscular diseases, Creative Biolabs provides the flexibility and technical expertise required to turn therapeutic concepts toward preclinical candidate development.